Ashley A Campbell1, Raksha Urs2, Alison B Callahan3, Ronald H Silverman2, Michael Kazim4. 1. Division of Oculoplastics and Reconstructive Surgery, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York. 3. Tufts New England Eye Center, Boston, Massachusetts. 4. Ophthalmic Plastic and Reconstructive, and Orbital Surgery Division, Department of Ophthalmology, New York Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, U.S.A.
Abstract
PURPOSE: Prior color-flow Doppler ultrasound studies of the eye have been performed with systems that exceed US Food and Drug Administration permissible ophthalmic ultrasonic energy limits. The authors report a study of orbital vascular malformations using a novel, Food and Drug Administration compliant, ultrafast compound coherent plane-wave ultrasound device to produce power Doppler images. METHODS: Using a Verasonics Vantage 128 ultrasound engine and a user-developed MATLAB program with a 5-MHz linear-array probe, compound coherent plane-wave ultrasound data were collected on patients with orbital vascular malformations. Real-time color-flow Doppler visualized orbital blood flow. Power Doppler images were produced by post-processing compound coherent plane-wave ultrasound data acquired continuously for 2 seconds. RESULTS: Compound coherent plane-wave ultrasound was performed on 3 orbital vascular malformations (1 venolymphatic malformation, 1 infantile hemangioma, and 1 arteriovenous malformation). Compound coherent plane-wave ultrasound produced a high-resolution depiction of orbital blood flow for orbital vascular malformations with high sensitivity to slow flow. CONCLUSIONS: Analysis of blood flow within orbital lesions informs treatment planning. Compound coherent plane-wave ultrasound is an emerging ultrasound modality that falls within the Food and Drug Administration guidelines for use in the orbit and provides information to characterize orbital vascular malformations.
PURPOSE: Prior color-flow Doppler ultrasound studies of the eye have been performed with systems that exceed US Food and Drug Administration permissible ophthalmic ultrasonic energy limits. The authors report a study of orbital vascular malformations using a novel, Food and Drug Administration compliant, ultrafast compound coherent plane-wave ultrasound device to produce power Doppler images. METHODS: Using a Verasonics Vantage 128 ultrasound engine and a user-developed MATLAB program with a 5-MHz linear-array probe, compound coherent plane-wave ultrasound data were collected on patients with orbital vascular malformations. Real-time color-flow Doppler visualized orbital blood flow. Power Doppler images were produced by post-processing compound coherent plane-wave ultrasound data acquired continuously for 2 seconds. RESULTS: Compound coherent plane-wave ultrasound was performed on 3 orbital vascular malformations (1 venolymphatic malformation, 1 infantile hemangioma, and 1 arteriovenous malformation). Compound coherent plane-wave ultrasound produced a high-resolution depiction of orbital blood flow for orbital vascular malformations with high sensitivity to slow flow. CONCLUSIONS: Analysis of blood flow within orbital lesions informs treatment planning. Compound coherent plane-wave ultrasound is an emerging ultrasound modality that falls within the Food and Drug Administration guidelines for use in the orbit and provides information to characterize orbital vascular malformations.
Authors: Giovanni H Greaves; Kym Livingston; Grant T Liu; Kenneth S Shindler; Nicholas J Volpe; Maxwell Pistilli; Sonul Mehta; Madhura A Tamhankar Journal: Orbit Date: 2017-07-13
Authors: S J Erickson; L E Hendrix; B M Massaro; G J Harris; M F Lewandowski; W D Foley; T L Lawson Journal: Radiology Date: 1989-11 Impact factor: 11.105
Authors: Raksha Urs; Jeffrey A Ketterling; Alfred C H Yu; Harriet O Lloyd; Billy Y S Yiu; Ronald H Silverman Journal: Transl Vis Sci Technol Date: 2018-09-04 Impact factor: 3.283